- Company name
- Halozyme Therapeutics
- Sector
- Drug delivery technology
- About
- Halozyme Therapeutics, Inc. (HALO) licenses drug delivery technology to drug companies. Its main technology, ENHANZE, uses rHuPH20, an enzyme that lets large drugs go under the skin instead of into a vein by infusion. Partners such as Janssen, Roche, argenx, Takeda, Pfizer and Bristol-Myers Squibb pay Halozyme upfront payments, milestones and royalties at an average mid-single-digit rate of their sales. The main royalty products are DARZALEX SC, Phesgo and VYVGART Hytrulo. Halozyme also sells bulk rHuPH20 and its own products. In 2025 it bought Elektrofi and Surf Bio, whose Hypercon and Aerocon technologies make drugs more concentrated. Halozyme reports in US dollars, and its shares trade on Nasdaq.
- Thesis
- The market weighs fast royalty growth against the end of the main ENHANZE patents. Halozyme says that an issued US patent on rHuPH20 expires in 2027 and that an issued European patent and other patents last into 2029. After that, other companies can try to make their own enzymes, and partners can have less reason to keep their agreements. Halozyme then depends on its MDASE patents, which expire from 2032 to 2034, and on the patents of each partner product. The AI estimate uses low multiples of 2027 earnings for this reason. For the price to rise, three things must be true. Royalties must keep growing from $341 million in Q3 2026, as partners launch new products and new uses. Courts must keep the MDASE patents valid, as the Dutch court did against Merck in October 2026. New collaborations and the Hypercon and Aerocon technologies must add revenue that lasts past 2030. The Q4 2026 results and the 2027 guidance, expected about February 5, 2027, are the next test, and the royalty trend and the patent cases in 2027 and 2028 show the direction. If royalties fall when the patents expire, the price can fall.
- Valuation
- The intrinsic value for Halozyme is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Halozyme. The method is a multiple of 2027 non-GAAP diluted earnings per share (EPS) less stock-based pay after tax. Non-GAAP EPS leaves out share-based compensation, the amortization of intangible assets and of debt discount, acquisition costs and the costs of the patent case against Merck. The Q3 2026 results (Form 8-K of November 5, 2026) give non-GAAP diluted EPS of $2.39 for Q3 2026 on 118.9 million non-GAAP diluted shares, share-based compensation of $16.8 million for the quarter and 2026 guidance of non-GAAP diluted EPS of $8.75 to $9.05. The estimate subtracts about $0.45 per share a year for stock-based pay after a tax rate of 21%, so 2026 is about $8.45 per share on this basis. The non-GAAP diluted share count includes the shares from the convertible notes due 2028, 2031 and 2032. Because EPS is after interest, the estimate makes no separate adjustment for the convertible notes, which had a principal of $3,307.8 million, or for cash and marketable securities of $1,074.4 million at September 30, 2026 (Form 10-Q). The cover of the Form 10-Q gives 114,010 thousand shares at October 31, 2026. The Form 10-K for 2025 says that an issued US patent on rHuPH20 expires in 2027, that an issued European patent and other patents last into 2029, and that the MDASE patents expire between 2032 and 2034. Royalties after these dates are less certain, so the estimate uses low multiples. The 2027 EPS and the multiples are assumptions. The low case assumes EPS after stock-based pay of $9.00, because royalty growth slows before the patents expire, at 9 times. It gives $81.00 per share. The base case assumes $10.25, about 21% more than in 2026, at 12 times. It gives $123.00 per share. The high case assumes $11.25 at 15 times. It gives $168.75 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $123.94 per share. The three cases are far apart. ENHANZE is part of the approved formulation of partner products such as DARZALEX SC, Phesgo and VYVGART Hytrulo, and a change of formulation needs a new regulatory approval, so partners rarely change. Halozyme also has the MDASE patents to 2034 and patents on its hyperconcentration technologies into the mid 2040s. These give an advantage that can last 10 years or more. But the main rHuPH20 patents expire from 2027 to 2029, and other companies can then try to make their own enzymes. The estimate uses no results after September 30, 2026.
As of Nov 14, 2026.
- Risks
- An issued US patent on rHuPH20 expires in 2027, and an issued European patent and other patents last into 2029. After that, other companies can make similar enzymes, and royalties can fall.
A few products give most royalties: DARZALEX SC, Phesgo and VYVGART Hytrulo. Lower sales of one of these products, or a change in the plans of a partner, reduce royalties.
Halozyme is in patent cases against Merck about the subcutaneous form of Keytruda. Courts in Germany and the Netherlands ordered Merck to stop sales in some countries, but appeals or other courts can decide the other way, and the cases cost money.
In June 2026, CMS proposed that, from price year 2029, Medicare drug price negotiation can treat a subcutaneous form made with an enzyme together with the intravenous form of the same drug. This can lower the US prices of partner products and so the royalties.
Convertible notes had a principal of $3,307.8 million at September 30, 2026. Above the conversion prices, such as $87.20 for the 2031 and 2032 notes, conversions can add shares, but capped calls reduce this.
- Balance sheet
- Cash: $1.1B
Debt: $3.3B
Net debt: $2.2B
Undrawn credit line: $750M, to November 2030
Debt due within 12 months: $58M
Last debt due: 2033
At September 30, 2026, Halozyme had cash and cash equivalents of $1,030.0 million and marketable securities of $44.4 million. Its debt was convertible notes with a principal of $3,307.8 million: $57.8 million due 2027, $250.0 million due 2028, $750.0 million due 2031, $750.0 million due 2032 and $1,500.0 million due 2033. Halozyme pays cash for the principal when holders convert. In September 2026, it issued the 2033 notes at 1.50% interest and used part of the money to buy back 2027 and 2028 notes. Nothing was drawn on the $750 million revolving credit facility, which matures on November 5, 2030 at the latest. In 2026, Halozyme repurchased $400 million of its shares.
As of Sep 30, 2026.
- Checkpoints
- Feb 5, 2027 (estimate): Q4 2026 results and 2027 guidance. Pending. Watch: 2026 royalty revenue is within or above the guidance of $1.235 billion to $1.255 billion and the 2027 guidance shows more royalty growth, and this passes; royalties below the range or no growth in the 2027 guidance fail.
2027 (estimate): MDASE patent cases. Pending. Watch: Courts keep the MDASE patents valid against Merck in 2027, and this passes; a decision that the main MDASE patent is invalid fails.
- Recent events
- Nov 5, 2026: Halozyme reported Q3 2026 results. Total revenue grew 39% to $493.0 million, royalty revenue grew 44% to $341.0 million, and non-GAAP diluted EPS was $2.39. It raised its 2026 guidance to total revenue of $1.860 billion to $1.925 billion and non-GAAP diluted EPS of $8.75 to $9.05. It also said that in October 2026 a Dutch patent court found that Merck infringes one of its MDASE patents and ordered Merck not to sell Keytruda Qlex in eight European countries.
Sep 22, 2026: Halozyme sold $1.5 billion of 1.50% convertible senior notes due 2033, with a conversion price of about $139.84 per share. It used part of the money to buy back convertible notes due 2027 and 2028 and to buy capped calls.
Jun 30, 2026: Halozyme changed its senior management structure, and its Chief Operating Officer, Cortney Caudill, left the company.
Apr 30, 2026: Halozyme named Darren Snellgrove, a former Chief Financial Officer of the pharmaceutical sector of Johnson & Johnson, as Chief Financial Officer from June 8, 2026.
Feb 17, 2026: Halozyme reported 2025 results. Total revenue grew 38% to a record $1.397 billion, and royalty revenue grew 52% to $868 million, led by DARZALEX SC, Phesgo and VYVGART Hytrulo.
Jan 28, 2026: Halozyme raised its 2026 guidance and announced the purchase of Surf Bio, which has a polymer technology for concentrated drugs, now called Aerocon.